Progressive Supranuclear Palsy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Progressive supranuclear palsy, also called Steele-Richardson-Olszewski syndrome is a rare neurodegenerative disease that leads to difficulty with balance, movement, vision, speech and swallowing. Symptoms include fatigue, headaches, dizziness, depression, Parkinsonism, behavioral, cognitive, and gait disturbances that cause imbalance and arthralgias. The only proven risk factor for progressive supranuclear palsy is age. Treatment includes anticholinergic medications.
The Progressive Supranuclear Palsy pipeline drugs market research report provides comprehensive information on the therapeutics under development for Progressive Supranuclear Palsy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report offers an overview of key players involved in therapeutic development for Progressive Supranuclear Palsy and features dormant and discontinued projects.
Progressive Supranuclear Palsy Pipeline Drugs Market Segmentation by Targets
Some of the targets of the Progressive Supranuclear Palsy pipeline drugs market are Microtubule Associated Protein Tau, Amyloid Beta A4 Protein, Protein O GlcNAcase, Alpha Synuclein, Free Radical, Major Prion Protein, and NADPH Oxidase 4 among others. Microtubule Associated Protein Tau leads this segment of the Progressive Supranuclear Palsy pipeline drugs market.
Progressive Supranuclear Palsy Pipeline Drugs Market Analysis, by Targets
For more Progressive Supranuclear Palsy pipeline drugs market target insights, download a free report sample
Progressive Supranuclear Palsy Pipeline Drugs Market Segmentation by Mechanisms of Action
Some of the key mechanisms of action of the Progressive Supranuclear Palsy pipeline drugs market are Microtubule Associated Protein Tau Inhibitor, Amyloid Beta A4 Protein Inhibitor, Protein O GlcNAcase Inhibitor, Alpha Synuclein Inhibitor, Free Radical Scavenger, and Major Prion Protein Inhibitor among others. Microtubule Associated Protein Tau Inhibitor leads the Progressive Supranuclear Palsy pipeline drugs market in terms of MoA.
Progressive Supranuclear Palsy Pipeline Drugs Market Analysis, by Mechanisms of Action
For more mechanisms of action insights into the Progressive Supranuclear Palsy pipeline drugs market, download a free report sample
Progressive Supranuclear Palsy Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the Progressive Supranuclear Palsy pipeline drugs market are Oral, Intravenous, Subcutaneous, Intrathecal, Ophthalmic, and Topical. Oral leads the Progressive Supranuclear Palsy pipeline drugs market in terms of RoA.
Progressive Supranuclear Palsy Pipeline Drugs Market Analysis, by Routes of Administration
For more routes of administration insights into the Progressive Supranuclear Palsy pipeline drugs market, download a free report sample
Progressive Supranuclear Palsy Pipeline Drugs Market Segmentation by Molecule Types
The molecule types in the Progressive Supranuclear Palsy pipeline drugs market are Small Molecule, Monoclonal Antibody, Antibody, Antisense Oligonucleotide, Gene Therapy, Gene-Modified Cell Therapy, and Subunit Vaccine. Small Molecule leads the Progressive Supranuclear Palsy pipeline drugs market in terms of molecule types.
Progressive Supranuclear Palsy Pipeline Drugs Market Analysis, by Molecule Types
For more molecule type insights into the Progressive Supranuclear Palsy pipeline drugs market, download a free report sample
Progressive Supranuclear Palsy Pipeline Drugs Market - Competitive Landscape
Some of the key companies in the Progressive Supranuclear Palsy pipeline drugs market are Aprinoia Therapeutics Inc, AlzProtect SAS, New Amsterdam Sciences Inc, UCB SA, Allyx Therapeutics Inc, Alterity Therapeutics Ltd, Anhorn Medicines Co Ltd, Arvinas Inc, and Asahi Kasei Pharma Corp among others. Aprinoia Therapeutics Inc has the highest number of products under development.
Progressive Supranuclear Palsy Pipeline Drugs Market Analysis, by Companies
To know more about the Progressive Supranuclear Palsy pipeline drugs companies, download a free report sample
Progressive Supranuclear Palsy Pipeline Drugs Market Report Overview
Key Targets | Microtubule Associated Protein Tau, Amyloid Beta A4 Protein, Protein O GlcNAcase, Alpha Synuclein, Free Radical, Major Prion Protein, and NADPH Oxidase 4 among others |
Key Mechanisms of Action | Microtubule Associated Protein Tau Inhibitor, Amyloid Beta A4 Protein Inhibitor, Protein O GlcNAcase Inhibitor, Alpha Synuclein Inhibitor, Free Radical Scavenger, and Major Prion Protein Inhibitor among others |
Key Routes of Administration | Oral, Intravenous, Subcutaneous, Intrathecal, Ophthalmic, and Topical |
Key Molecule Types | Small Molecule, Monoclonal Antibody, Antibody, Antisense Oligonucleotide, Gene Therapy, Gene-Modified Cell Therapy, and Subunit Vaccine |
Key Companies | Aprinoia Therapeutics Inc, AlzProtect SAS, New Amsterdam Sciences Inc, UCB SA, Allyx Therapeutics Inc, Alterity Therapeutics Ltd, Anhorn Medicines Co Ltd, Arvinas Inc, and Asahi Kasei Pharma Corp among others |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Progressive Supranuclear Palsy.
- The pipeline guide reviews pipeline therapeutics for Progressive Supranuclear Palsy by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Progressive Supranuclear Palsy therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Progressive Supranuclear Palsy therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Progressive Supranuclear Palsy
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Progressive Supranuclear Palsy.
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding the Progressive Supranuclear Palsy pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.
Alterity Therapeutics Ltd
AlzProtect SAS
Anhorn Medicines Co Ltd
Aprinoia Therapeutics Inc
Arvinas Inc
Asahi Kasei Pharma Corp
Asceneuron SA
AZTherapies Inc
Cortice Biosciences Inc
Merck & Co Inc
NeuroTau Inc
New Amsterdam Sciences Inc
Novartis AG
Pinteon Therapeutics Inc
ProMIS Neurosciences Inc
Prothena Corp Plc
Reata Pharmaceuticals Inc
Retrotope Inc
TauC3 Biologics Ltd
TauRx Therapeutics Ltd
Transposon Therapeutics Inc
UCB SA
Vaxxinity Inc
Verge Genomics
Voyager Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets of the Progressive Supranuclear Palsy pipeline drugs market?
Some of the targets of the Progressive Supranuclear Palsy pipeline drugs market are Microtubule Associated Protein Tau, Amyloid Beta A4 Protein, Protein O GlcNAcase, Alpha Synuclein, Free Radical, Major Prion Protein, and NADPH Oxidase 4 among others.
-
What are the key mechanisms of action in the Progressive Supranuclear Palsy pipeline drugs market?
Some of the mechanisms of action of the Progressive Supranuclear Palsy pipeline drugs market are Microtubule Associated Protein Tau Inhibitor, Amyloid Beta A4 Protein Inhibitor, Protein O GlcNAcase Inhibitor, Alpha Synuclein Inhibitor, Free Radical Scavenger, and Major Prion Protein Inhibitor among others.
-
What are the key routes of administration in the Progressive Supranuclear Palsy pipeline drugs market?
The key routes of administration in the Progressive Supranuclear Palsy pipeline drugs market are Oral, Intravenous, Subcutaneous, Intrathecal, Ophthalmic, and Topical.
-
What are the key molecule types in the Progressive Supranuclear Palsy pipeline drugs market?
The molecule types in the Progressive Supranuclear Palsy pipeline drugs market are Small Molecule, Monoclonal Antibody, Antibody, Antisense Oligonucleotide, Gene Therapy, Gene-Modified Cell Therapy, and Subunit Vaccine.
-
Which are the leading companies in the Progressive Supranuclear Palsy pipeline drugs market?
Some of the leading companies in the Progressive Supranuclear Palsy pipeline drugs market are Aprinoia Therapeutics Inc, AlzProtect SAS, New Amsterdam Sciences Inc, UCB SA, Allyx Therapeutics Inc, Alterity Therapeutics Ltd, Anhorn Medicines Co Ltd, Arvinas Inc, and Asahi Kasei Pharma Corp among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.